JP2018520352A5 - - Google Patents

Download PDF

Info

Publication number
JP2018520352A5
JP2018520352A5 JP2017567207A JP2017567207A JP2018520352A5 JP 2018520352 A5 JP2018520352 A5 JP 2018520352A5 JP 2017567207 A JP2017567207 A JP 2017567207A JP 2017567207 A JP2017567207 A JP 2017567207A JP 2018520352 A5 JP2018520352 A5 JP 2018520352A5
Authority
JP
Japan
Prior art keywords
aryl
alkylene
alkyl
pharmaceutical composition
heterocycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2017567207A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018520352A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/038983 external-priority patent/WO2016210106A1/en
Publication of JP2018520352A publication Critical patent/JP2018520352A/ja
Publication of JP2018520352A5 publication Critical patent/JP2018520352A5/ja
Priority to JP2021128745A priority Critical patent/JP2021185146A/ja
Ceased legal-status Critical Current

Links

JP2017567207A 2015-06-23 2016-06-23 アルギナーゼ活性を阻害するための組成物および方法 Ceased JP2018520352A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021128745A JP2021185146A (ja) 2015-06-23 2021-08-05 アルギナーゼ活性を阻害するための組成物および方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562183524P 2015-06-23 2015-06-23
US62/183,524 2015-06-23
PCT/US2016/038983 WO2016210106A1 (en) 2015-06-23 2016-06-23 Compositions and methods for inhibiting arginase activity

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021128745A Division JP2021185146A (ja) 2015-06-23 2021-08-05 アルギナーゼ活性を阻害するための組成物および方法

Publications (2)

Publication Number Publication Date
JP2018520352A JP2018520352A (ja) 2018-07-26
JP2018520352A5 true JP2018520352A5 (enExample) 2019-07-25

Family

ID=57585664

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017567207A Ceased JP2018520352A (ja) 2015-06-23 2016-06-23 アルギナーゼ活性を阻害するための組成物および方法
JP2021128745A Withdrawn JP2021185146A (ja) 2015-06-23 2021-08-05 アルギナーゼ活性を阻害するための組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021128745A Withdrawn JP2021185146A (ja) 2015-06-23 2021-08-05 アルギナーゼ活性を阻害するための組成物および方法

Country Status (17)

Country Link
US (4) US10143699B2 (enExample)
EP (1) EP3313410A4 (enExample)
JP (2) JP2018520352A (enExample)
KR (1) KR20180021117A (enExample)
CN (1) CN107921051A (enExample)
AU (1) AU2016281620B2 (enExample)
CA (1) CA2990192A1 (enExample)
EA (1) EA201890113A1 (enExample)
IL (1) IL256352A (enExample)
MA (1) MA42269A (enExample)
MX (1) MX385315B (enExample)
MY (1) MY192605A (enExample)
PH (1) PH12017502391A1 (enExample)
SG (1) SG10202110144TA (enExample)
UA (1) UA123700C2 (enExample)
WO (1) WO2016210106A1 (enExample)
ZA (1) ZA201800328B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2560978B1 (en) 2010-04-22 2019-01-30 Mars, Incorporated Inhibitors of arginase and their therapeutic applications
EP3034509B1 (en) 2010-10-26 2020-04-22 Mars, Incorporated Arginase inhibitors as therapeutics
AU2016281620B2 (en) 2015-06-23 2021-07-22 Calithera Biosciences, Inc. Compositions and methods for inhibiting arginase activity
DK3368541T3 (da) * 2015-10-30 2020-06-29 Calithera Biosciences Inc Sammensætninger og metoder til inhibiering af arginaseaktivitet
PL417066A1 (pl) 2016-05-04 2017-11-06 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Inhibitory arginazy oraz ich zastosowania terapeutyczne
US11291674B2 (en) 2016-11-08 2022-04-05 Calithera Biosciences, Inc. Arginase inhibitor combination therapies
WO2018119440A1 (en) 2016-12-22 2018-06-28 Calithera Biosciences, Inc. Compositions and methods for inhibiting arginase activity
CN108794517B (zh) * 2017-04-27 2021-03-30 南京谷睿生物科技有限公司 一种精氨酸酶抑制剂及其制备方法与用途
KR20200008578A (ko) 2017-05-12 2020-01-28 칼리테라 바이오사이언시즈, 인코포레이티드 (3R,4S)-3-아세트아미도-4-알릴-N-(tert-부틸)피롤리딘-3-카복스아미드의 제조방법
WO2019000163A1 (zh) * 2017-06-26 2019-01-03 余祖江 精氨酸在制备抗肿瘤药物中的用途
CN111491937A (zh) * 2017-12-22 2020-08-04 广东新契生物医药科技有限公司 作为精氨酸酶抑制剂的杂环化合物
SG11202007739XA (en) 2018-02-17 2020-09-29 Astrazeneca Ab Arginase inhibitors and methods of use thereof
WO2019173188A1 (en) * 2018-03-05 2019-09-12 Arcus Biosciences, Inc. Arginase inhibitors
AU2019246728A1 (en) 2018-03-29 2020-08-27 Oncoarendi Therapeutics S.A. Dipeptide piperidine derivatives
WO2019205979A1 (zh) * 2018-04-27 2019-10-31 四川科伦博泰生物医药股份有限公司 非天然氨基酸类衍生物、包含其的药物组合物及其制备方法和用途
MA53427B1 (fr) * 2018-08-22 2024-06-28 Astrazeneca Ab Inhibiteurs de l'arginase et leurs méthodes d'utilisation
EP3880685B1 (en) * 2018-11-16 2025-06-18 Arcus Biosciences, Inc. Inhibitors of arg1 and/or arg2
EP3883938A1 (en) * 2018-11-21 2021-09-29 Praxis Biotech LLC Inhibitors of arginase
CN113614095B (zh) * 2019-02-06 2024-08-23 广东新契生物医药科技有限公司 作为精氨酸酶抑制剂的烷基硼酸类化合物
MY206577A (en) * 2019-02-08 2024-12-24 Astrazeneca Ab Arginase inhibitors and methods of use thereof
US10967020B2 (en) * 2019-04-05 2021-04-06 King Saud University Method of synthesizing custard apple peel nanoparticles
CN112110944B (zh) * 2019-06-21 2022-02-11 南京谷睿生物科技有限公司 一种化合物及其制备方法和应用
EP4004004A1 (en) * 2019-07-23 2022-06-01 AstraZeneca AB Arginase inhibitors and methods of use thereof
CN110734456A (zh) * 2019-11-06 2020-01-31 南京谷睿生物科技有限公司 一种化合物及其制备方法和医药上的应用
TW202228720A (zh) 2020-12-22 2022-08-01 波蘭商昂科艾倫迪治療法股份公司 精胺酸酶抑制劑及其使用方法
WO2023191116A2 (en) 2022-01-21 2023-10-05 Opiyo Sammy Oyoo Improved suramin methods and compositions
KR20260082234A (ko) * 2024-11-27 2026-06-04 주식회사 대웅제약 아르기나아제 저해제 및 이를 포함하는 약학적 조성물

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4172896A (en) 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
GB9217295D0 (en) 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
US5541231A (en) 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
GB9315856D0 (en) 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
US5358970A (en) 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
DE69818675T2 (de) 1997-07-29 2004-07-29 Alcon Laboratories, Inc., Fort Worth Galaktomannanpolymere und borat enthaltende augenarzneimittel
AU9797998A (en) 1997-10-10 1999-05-03 Trustees Of The University Of Pennsylvania, The Compositions and methods for inhibiting arginase activity
AU2483599A (en) 1998-01-29 1999-08-16 Sepracor, Inc. Pharmaceutical uses of optically pure (-)-bupropion
US20040063666A1 (en) 1998-10-09 2004-04-01 David Christianson Compositions for inhibiting arginase activity
US8889112B2 (en) 1999-09-16 2014-11-18 Ocularis Pharma, Llc Ophthalmic formulations including selective alpha 1 antagonists
WO2002004465A1 (en) * 2000-07-06 2002-01-17 Fal Diagnostics Methods and kits for the detection of arginine compounds
CA2431080A1 (en) 2003-06-02 2004-12-02 Catherine Adele O'brien Enhancement of anticancer immunity through inhibition of arginase
US6933289B2 (en) 2003-07-01 2005-08-23 Allergan, Inc. Inhibition of irritating side effects associated with use of a topical ophthalmic medication
EP1654002B2 (en) 2003-08-07 2014-01-29 Allergan, Inc. Compositions for delivery of therapeutics into the eyes
US20050059744A1 (en) 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
EP1915143A4 (en) 2005-07-01 2009-11-11 Univ Johns Hopkins ARGINASE II: TARGET TREATMENT FOR THE AGING HEART AND HEART FAILURE
CN101755130B (zh) 2007-07-12 2012-10-17 山洋电气株式会社 双重反转式轴流鼓风机
WO2010085797A2 (en) 2009-01-26 2010-07-29 The Trustees Of University Of Pennsylvania Arginase inhibitors and methods of use
EP2560978B1 (en) 2010-04-22 2019-01-30 Mars, Incorporated Inhibitors of arginase and their therapeutic applications
EP3034509B1 (en) * 2010-10-26 2020-04-22 Mars, Incorporated Arginase inhibitors as therapeutics
RU2019121905A (ru) 2010-12-31 2019-09-03 Астразенека Юкей Лимитед Ингибиторы аргиназы и способы их применения
CA2852685C (en) 2011-10-19 2019-02-26 Mars, Incorporated Inhibitors of arginase and their therapeutic application
KR20140077963A (ko) 2011-10-20 2014-06-24 글락소스미스클라인 엘엘씨 시르투인 조절제로서의 치환된 비시클릭 아자-헤테로사이클 및 유사체
CN104540836B (zh) * 2012-04-18 2016-11-09 马尔斯公司 作为精氨酸酶抑制剂的环约束类似物
WO2015061752A1 (en) 2013-10-25 2015-04-30 Pharmacyclics, Inc. Treatment using bruton's tyrosine kinase inhibitors and immunotherapy
CN105879030A (zh) 2014-09-30 2016-08-24 复旦大学 治疗肿瘤的增效药物复合物及其制备方法
KR20170129896A (ko) 2015-03-20 2017-11-27 새미 오유 오피요 악성 신생물에 대한 수라민 및 아르기나아제 억제제의 용도
AU2016281620B2 (en) 2015-06-23 2021-07-22 Calithera Biosciences, Inc. Compositions and methods for inhibiting arginase activity

Similar Documents

Publication Publication Date Title
JP2010501584A5 (enExample)
JP2020531422A5 (enExample)
JP2012525393A5 (enExample)
JP2016529245A5 (enExample)
JP2016040288A5 (enExample)
EP3801025A4 (en) Composition and methods of controllable co-coupling polypeptide nanoparticle delivery system for nucleic acid therapeutics
JP2015511638A5 (enExample)
RU2015118647A (ru) Аминопиримидиновые соединения в качестве ингибиторов содержащих т790м мутантных egfr
JP2018519343A5 (enExample)
JP2017523225A5 (enExample)
JP2017528498A5 (enExample)
JP2016515561A5 (enExample)
JP2015536964A5 (enExample)
JP2016521256A5 (enExample)
JP2020532547A5 (enExample)
JP2017526677A5 (enExample)
JP2014508804A5 (enExample)
JP2017531673A5 (enExample)
JP2016516074A5 (enExample)
JP2015524472A5 (enExample)
EP3325080A4 (en) METHOD FOR BETTER ADMINISTRATION OF AGENTS AGAINST TUMORS
JP2018502824A5 (enExample)
JP2016531126A5 (enExample)
JP2016501066A5 (enExample)
KR20160066554A (ko) 브루톤 타이로신 키나제 억제제 및 면역요법을 이용한 치료